

Table 2: Antiviral treatment characteristics of patients with chronic hepatitis C overall and by hepatitis C virus (HCV) genotype.

	Genotype					
	1	2	3	4	Overall	
	N (%)	N (%)	N (%)	N (%)	N (%)	p-value
HCV-treatment naive						<0.001
Yes	289 (71.4)	73 (90.1)	310 (91.2)	87 (69.6)	759 (79.8)	
No	116 (28.6)	8 (9.9)	30 (8.8)	38 (30.4)	192 (20.2)	
Type of treatment						0.432
PEG-IFN α -2a + RIB	170 (42.0)	36 (44.4)	161 (47.4)	51 (40.8)	418 (44.0)	
PEG-IFN α -2b + RIB	235 (58.0)	45 (55.6)	179 (52.6)	74 (59.2)	533 (56.0)	
Treatment discontinuation	125 (30.9)	12 (14.8)	65 (19.1)	37 (29.6)	239 (25.1)	<0.001
Reason for treatment discontinuation						0.004
Non-response	27 (21.6)	2 (16.7)	7 (10.8)	10 (27.0)	46 (19.2)	
Side-effects	68 (54.4)	9 (75.0)	34 (52.3)	17 (45.9)	128 (53.6)	
Non-compliance	20 (16.0)	1 (8.3)	24 (36.9)	10 (27.0)	55 (23.0)	
Unknown	10 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	10 (4.2)	
Response to treatment[†]						<0.001
Non responders	118 (41.5)	11 (17.7)	32 (12.7)	42 (46.7)	203 (29.5)	
Responders/Relapsers	33 (11.6)	5 (8.1)	23 (9.2)	9 (10.0)	70 (10.2)	
Responders	133 (46.8)	46 (74.2)	196 (78.1)	39 (43.3)	414 (60.3)	
Sustained virologic response (overall)[‡]	133 (37.6)	46 (64.8)	196 (72.9)	39 (37.1)	414 (51.8)	<0.001

[†]N=687 for those with available laboratory or clinical information at the end of treatment and at 6 months afterwards, [‡]N=799 for those with available laboratory or clinical information at 6 months after the end of treatment.